Quantitative risk reduction through peanut immunotherapy: Safety benefits of an increased threshold in Europe.
Benjamin C RemingtonTanja KroneStef J KoppelmanPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2019)
It is concluded that an increase in threshold following immunotherapy which achieves an eliciting dose of 300 or 1000 mg peanut protein is clinically relevant for the European peanut-allergic population. Benefits of an increased threshold include a significant reduction in risk due to traces of peanut protein.